Further experiments indicated that ERO1α promoted tumor angiogenesis and positively correlated with VEGF-A expression via the S1PR1/STAT3/VEGF-A pathway, suggesting that ERO1α may be a novel therapeutic target for inhibiting tumor angiogenesis. The gene discussed is S1PR1; the disease is neoplasm.